Shots:
- Enlaza & Vertex’s muti-target collaboration will leverage Enlaza’s War-Lock platform to develop small format drug conjugates & T-cell engagers for autoimmune diseases & improved conditioning in sickle cell disease & β thalassemia
- Enlaza will receive $45M in upfront & equity investment & is eligible for >$2B in research, development, regulatory, & commercial milestones plus tiered royalties; it will lead research to candidate nomination, with Vertex funding the 4yr. collaboration & assuming all subsequent R&D, manufacturing, & commercialization
- War-Lock platform uses proprietary non-natural amino acids to create covalent proteins with small-format biologic selectivity to expand the therapeutic window across modalities
Ref: Enlaza| Image: Enlaza & Vertex | Press Release
Related News:- IDEAYA Biosciences Partners with Servier to Develop and Commercialize Darovasertib for Uveal Melanoma (UM)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
